출혈우세병변이 동반된 연령관련 황반변성 환자에서의 유리체강 내 라니비주맙 주입술의 효과

Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration with a Predominantly Hemorrhagic Lesion

Purpose: To report the efficacy and safety of intravitreal ranibizumab monotherapy in patients with age-related macular degeneration with a predominantly hemorrhagic lesion. Methods: Nineteen eyes of 19 patients with submacular hemorrhage involving the fovea were treated with intravitreal ranibizumab (0.5 mg/0.05 ml) injections as needed. All patients completed at least 4 months of follow-up. Ophthalmologic examinations, fluorescence angiographic evaluations, optical coherence tomography (OCT) examination, and hemorrhage size were analyzed before the injections, and at 1,2,4,6, and 12 months follow-up. Results: The average VA and mean central retinal thickness (CRT) before ranibizumab treatment were 0.62 ± 0.39 log MAR and 335.76 ± 111.22 μm, respectively. Additionally, the VA and CRT four months after the initial injections were 0.54 ± 0.43 log MAR and 241.42 ± 107.55 μm, respectively. The mean size of the hemorrhage was significantly reduced from 2.87 ± 2.44 DA (disk areas) at baseline to 0.9 ± 1.28 DA at four month follow up. Conclusions: Intravitreal injection of ranibizumab is an effective treatment option for patients with age-related macular degeneration with a predominantly hemorrhagic lesion. J Korean Ophthalmol Soc 2011;52(7):838-845